Latest Thiazoles Stories
TAMPA, Fla., Nov.
Drug associated with a life-threatening heart abnormality when used with another antiviral medicine SILVER SPRING, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S.
TAMPA, Fla., Oct. 21 /PRNewswire/ -- Romark Laboratories, L.C.
TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.
TAMPA, Fla., April 15 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.
NORTHBROOK, Ill. and REINACH, Switzerland, April 1 /PRNewswire/ -- Horizon Therapeutics, Inc. and Nitec Pharma AG, both privately held companies, today announced a definitive agreement in which the two companies have combined in an all-stock transaction.
TAMPA, Fla., Feb. 1 /PRNewswire/ -- Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of AliniaÂ® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.
SCHAUMBURG, Ill., Dec. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of two antibiotics: cefoxitin for injection, USP and ceftriaxone for injection, USP.
Wild birds of several species are dying in large numbers from a paralytic disease with hitherto unknown cause in the Baltic Sea area. A research team at Stockholm University, Sweden
Editorial Accompanies Manuscript in March Issue TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroenterology, the official journal of the American Gastroenterological Association Institute (AGA Institute).